Financial Performance - The net profit attributable to shareholders increased by 49.79% year-on-year, driven by both the net profit excluding non-recurring gains and losses and the growth of non-recurring gains and losses[6]. - The net profit from laboratory services reached RMB 70.12 million, representing a year-on-year growth of 33.79% compared to RMB 52.41 million in the same period last year[13]. - The net profit excluding non-recurring gains and losses grew by 39.56% year-on-year[13]. - The net profit attributable to shareholders for Q1 2023 was CNY 187,759,654.85, reflecting a growth of 49.79% compared to the same period last year[33]. - Net profit for Q1 2023 was CNY 187,710,078.62, compared to CNY 124,879,519.42 in Q1 2022, indicating a 50.3% year-over-year growth[49]. - The total comprehensive income for Q1 2023 was CNY 183,307,433.87, compared to CNY 123,848,015.54 in Q1 2022, marking an increase of about 47.9%[50]. - Basic earnings per share for Q1 2023 were CNY 0.35, an increase of 45.83% year-on-year[33]. - Basic and diluted earnings per share for Q1 2023 were both CNY 0.35, compared to CNY 0.24 in Q1 2022, reflecting a year-over-year increase of about 45.8%[50]. Revenue and Costs - The company's operating revenue for Q1 2023 was CNY 369,386,010.95, representing a year-on-year increase of 36.32%[33]. - Total revenue for Q1 2023 reached CNY 369,386,010.95, a 36.3% increase from CNY 270,975,486.87 in Q1 2022[47]. - Total operating costs for Q1 2023 were CNY 262,811,341.25, up from CNY 178,514,884.87 in Q1 2022, reflecting a significant increase in operational expenses[49]. - Research and development expenses for Q1 2023 amounted to CNY 27,611,585.58, significantly higher than CNY 12,289,064.34 in Q1 2022, highlighting the company's commitment to innovation[49]. Assets and Liabilities - The total assets at the end of Q1 2023 amounted to CNY 10,548,083,755.28, a 1.77% increase from the end of the previous year[34]. - The total assets increased to CNY 10,548,083,755.28 from CNY 10,364,215,494.62, showing a growth of 1.8%[46]. - The total liabilities rose to CNY 2,185,937,338.52, compared to CNY 2,173,349,441.47, reflecting a 0.6% increase[47]. - The company's equity attributable to shareholders increased to CNY 8,355,031,298.11 from CNY 8,183,701,358.27, representing a growth of 2.1%[47]. Cash Flow - The net cash flow from operating activities for Q1 2023 was -CNY 13,668,184.06, a decrease of 118.25% compared to the previous year[33]. - Cash flow from operating activities for Q1 2023 was CNY 613,167,483.43, slightly up from CNY 607,592,750.32 in Q1 2022, indicating a growth of approximately 0.9%[50]. - The ending balance of cash and cash equivalents as of the end of Q1 2023 was CNY 2,961,151,889.94, down from CNY 4,320,056,146.25 at the end of Q1 2022[52]. - The cash inflow from financing activities in Q1 2023 included CNY 30,758,211.00 from investment received, while cash outflow for debt repayment was CNY 861,696.20[52]. - The impact of exchange rate changes on cash and cash equivalents for Q1 2023 was -CNY 6,273,367.27, compared to -CNY 3,212,750.12 in Q1 2022[52]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 53,574[19]. - The largest shareholder, Feng Yuxia, holds 22.29% of the shares, totaling 119,400,452 shares[19]. Non-Recurring Gains and Losses - Non-recurring gains and losses amounted to RMB 3.01 million, with specific contributions including government subsidies of RMB 4.05 million[17]. - Non-recurring gains and losses included a loss from the disposal of non-current assets amounting to -CNY 51,902.64[36]. Future Outlook - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[48]. - The company has seen a significant month-on-month improvement in new orders signed as of the report date[21]. - New orders signed during the period were approximately RMB 570 million, a year-on-year decrease of about 43%, with a backlog of orders totaling approximately RMB 4.6 billion[21].
昭衍新药(603127) - 2023 Q1 - 季度财报